EURETINA – Original Paper
Retinal Pigment Epithelium Tears in Age-Related Macular Degeneration Treated with Antiangiogenic Drugs: A Controlled Study with Long Follow-UpCoco R.M.a · Sanabria M.R.a, b · Hernandez A.G.a · Fernández Muñoz M.b
aInstitute of Applied Ophthalmobiology (IOBA), University of Valladolid, Valladolid, and bComplejo Asistencial de Palencia, Palencia, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Purpose: To study whether anti-vascular endothelial growth factor (VEGF) therapy improves visual acuity (VA) in patients with exudative age-related macular degeneration (AMD) complicated with retinal pigment epithelium (RPE) tears. Methods: Retrospective case-control series. Group I (control group) included 9 patients with RPE tears that received no treatment, and group II (intervention group) incorporated 12 patients treated with anti-VEGF. Results: A statistically significant difference was found in VA between the groups from the 3rd month to the final follow-up (p = 0.034). Final VA improved in the treatment group (p = 0.015). No differences were found in central macular thickness between the groups either before or after treatment. Mean number of injections in group II was 5.75 (SD = 1.19). Most patients presented a grade 3 rip. All lesions were inactive at the end of follow-up in group II and 1 remained active in group I. The number of final atrophic/disciform scars was 6/8 in group I and 7/5 in group II. Conclusions: RPE tears treated with antiangiogenic drugs experienced functional benefit. To the authors’ knowledge, this is the first controlled series reporting effectiveness of suppression of neovascular activity with antiangiogenic treatment after RPE rip in AMD.
© 2012 S. Karger AG, Basel
- Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol 1997;115:741–747.
- Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M: Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508–1525.
- Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.
- Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
- Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372.
- Hoskin A, Bird AC, Sehmi K: Tears of detached retinal pigment epithelium. Br J Ophthalmol 1981;65:417–422.
- Zayit-Soudry S, Moroz I, Loewenstein A: Retinal pigment epithelial detachment. Surv Ophthalmol 2007;52:227–243.
- Decker WL, Sanborn GE, Ridley M, Annesley WH Jr, Sorr EM: Retinal pigment epithelial tears. Ophthalmology 1983;90:507–512.
- Norose K, Tanino T, Segawa K: Bilateral tears of the retinal pigment epithelium. Br J Ophthalmol 1988;72:621–627.
- Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I: Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 2001;131:518–520.
- Goldstein M, Heilweil G, Barak A, Loewenstein A: Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye (Lond) 2005;19:1315–1324.
- Michels S, Aue A, Simader C, Geitzenauer W, Sacu S, Schmidt-Erfurth U: Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone. Am J Ophthalmol 2006;141:396–398.
- Pece A, Introini U, Bottoni F, Brancato R: Acute retinal pigment epithelial tear after photodynamic therapy. Retina 2001;21:661–665.
- Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT, Lin SG, Rauser ME, Kaiser PK: Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007;27:541–551.
- Chang LK, Sarraf D: Tears of the retinal pigment epithelium: an old problem in a new era. Retina 2007;27:523–534.
- Dhalla MS, Blinder KJ, Tewari A, Hariprasad SM, Apte RS: Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 2006;141:752–754.
- Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D: Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 2008;36:252–256.
- Konstantinidis L, Ambresin A, Zografos L, Mantel I: Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration. Acta Ophthalmol 2010;88:736–741.
- Ronan SM, Yoganathan P, Chien FY, Corcostegui IA, Blumenkranz MS, Deramo VA, Elner SG, Fastenberg DA, Johnson MW, Lopez M, Mateo C, Moshfeghi DM, Navarro R, Rosenblatt BJ, Sanislo SR, Saxe SJ, Zacks DN: Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2007;27:535–540.
- Singh RP, Sears JE: Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration. Am J Ophthalmol 2006;142:160–162.
- Weinberger AW, Thiel M, Mohammadi B, Theofylaktopoulos I, Thumann G, Walter P: Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 2007;144:294–296.
- Chuang EL, Bird AC: Bilaterality of tears of the retinal pigment epithelium. Br J Ophthalmol 1988;72:918–920.
- Chan CK, Abraham P, Meyer CH, Kokame GT, Kaiser PK, Rauser ME, Gross JG, Nuthi AS, Lin SG, Daher NS: Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 2010;30:203–211.
- Chiang A, Chang LK, Yu F, Sarraf D: Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 2008;28:1265–1269.
- Chan CK, Lin SG: Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol 2007;17:674–676.
- Gutfleisch M, Heimes B, Schumacher M, Dietzel M, Lommatzsch A, Bird A, Pauleikhoff D: Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD. Eye (Lond) 2011;25:1181–1186.
- Lesniak SP, Fine HF, Prenner JL, Roth DB: Long-term follow-up of spontaneous retinal pigment epithelium tears in age-related macular degeneration treated with anti-VEGF therapy. Eur J Ophthalmol 2011;21:73–76.
- Rouvas AA: Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial tear. Retina 2011;31:1083–1088.
- Giovannini A, Amato G, Mariotti C, Scassellati-Sforzolini B: Optical coherence tomography in the assessment of retinal pigment epithelial tear. Retina 2000;20:37–40.
- Sarraf D, Reddy S, Chiang A, Yu F, Jain A: A new grading system for retinal pigment epithelial tears. Retina 2010;30:1039–1045.
- Spaide R: Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679–680.
- Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566–583.
- Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43–58.
- Meredith TA, Braley RE, Aaberg TM: Natural history of serous detachments of the retinal pigment epithelium. Am J Ophthalmol 1979;88:643–651.
- Poliner LS, Olk RJ, Burgess D, Gordon ME: Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology 1986;93:543–551.
- Slakter JS, Yannuzzi LA, Sorenson JA, Guyer DR, Ho AC, Orlock DA: A pilot study of indocyanine green videoangiography-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1994;112:465–472.
- Casswell AG, Kohen D, Bird AC: Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 1985;69:397–403.
- Peiretti E, Iranmanesh R, Lee JJ, Klancnik JM Jr, Sorenson JA, Yannuzzi LA: Repopulation of the retinal pigment epithelium after pigment epithelial rip. Retina 2006;26:1097–1099.
- Polito A, Cereda M, Romanelli F, Pertile G: Macular translocation with 360 degrees retinotomy for management of retinal pigment epithelial tear: long-term results. Br J Ophthalmol 2011;95:74–78.
- Caramoy A, Kirchhof B, Fauser S: Retinal pigment epithelium tears secondary to age-related macular degeneration: a simultaneous confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography study. Arch Ophthalmol 2011;129:575–579.
- Karadimas P, Paleokastritis GP, Bouzas EA: Fundus autofluorescence imaging findings in retinal pigment epithelial tear. Eur J Ophthalmol 2006;16:767–769.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.